Serodus ASA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Serodus ASA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10531
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Serodus ASA (Serodus) is a drug development company that develops treatments for unmet clinical needs in the areas of diabetes and diabetic comorbidities. The company’s pipeline products include SER150DN, an anti-inflammatory compound under development for diabetic nephropathy; SER130AMI, an interleukin-4 agonist for acute myocardial infarction; SER100PH, for group I or IV pulmonary hypertension; SER140T2D; and SER190DFU. Its pipeline product SER190 is an IL-1beta receptor antagonist IL-1Ra, which provide wound healing with biological process in three phases such as inflammation, proliferation and maturation. The company enters into licensing arrangements and collaborates with biotech companies and universities to develop its product pipeline. Serodus is headquartered in Oslo, Norway.

Serodus ASA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Serodus ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Serodus ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Serodus ASA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Serodus Raises US$0.09 Million In Venture Financing 10
Licensing Agreements 11
Evolva And Serodus Enter Into Licensing Agreement For EV-077 11
Equity Offering 12
Serodus Raises USD1.2 Million in Private Placement of Shares 12
Serodus to Raise up to USD3.7 Million in Rights Offering of Shares 13
Serodus Completes Public Offering of Shares for USD1.71 Million 14
Serodus Completes Private Placement Of Shares For US$4.9 Million 15
Serodus Completes IPO Of US$0.7 Million 16
Acquisition 18
Viggo Harboe Holding 2006 to Acquire Additional 8.1% Stake in Serodus 18
Serodus Completes Acquisition of Phlogo for USD0.9 Million 19
Serodus ASA – Key Competitors 20
Serodus ASA – Key Employees 21
Serodus ASA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Feb 27, 2017: Serodus: Results for Q4-2016 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Serodus ASA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Serodus ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Serodus ASA, Deals By Therapy Area, 2012 to YTD 2018 8
Serodus ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Serodus Raises US$0.09 Million In Venture Financing 10
Evolva And Serodus Enter Into Licensing Agreement For EV-077 11
Serodus Raises USD1.2 Million in Private Placement of Shares 12
Serodus to Raise up to USD3.7 Million in Rights Offering of Shares 13
Serodus Completes Public Offering of Shares for USD1.71 Million 14
Serodus Completes Private Placement Of Shares For US$4.9 Million 15
Serodus Completes IPO Of US$0.7 Million 16
Viggo Harboe Holding 2006 to Acquire Additional 8.1% Stake in Serodus 18
Serodus Completes Acquisition of Phlogo for USD0.9 Million 19
Serodus ASA, Key Competitors 20
Serodus ASA, Key Employees 21
Serodus ASA, Subsidiaries 22

List of Figures
Serodus ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Serodus ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Serodus ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Serodus ASA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AltheaDx Inc-医療機器分野:企業M&A・提携分析
    Summary AltheaDx Inc (AltheaDx) is a biotechnology company that offers molecular diagnostic services. The company provides tests such as cardiovascular tests, pain tests, thrombophilia tests and psychiatric tests. It provides diagnostic development, clinical trial and discovery services. AltheaDx’ s …
  • Aristocrat Leisure Ltd (ALL):企業の財務・戦略的SWOT分析
    Aristocrat Leisure Ltd (ALL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Astellas Pharma Europe Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Astellas Pharma Europe Ltd (Astellas Pharma), a subsidiary of Astellas Pharma Inc is a manufacturer and distributor of drug products. The company provides pharmaceutical drugs in the areas of oncology, transplantation, urology, anti-infective, pain management and dermatology. It also provide …
  • Evofem Biosciences Inc (EVFM):製薬・医療:M&Aディール及び事業提携情報
    Summary Evofem Biosciences Inc (Evofem) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes reproductive and contraceptive care products for women. The company’s lead product candidate includes Amphora, a non-hormonal vaginal contraceptive gel for the prevention …
  • Emerald Health Therapeutics Inc (EMH):製薬・医療:M&Aディール及び事業提携情報
    Summary Emerald Health Therapeutics Inc (Emerald Health), formerly T-Bird Pharma Inc, is a producer of pharmaceutical grade medical cannabis. The company extracts and markets dried cannabis, and cannabis oils and capsules. It offers cannabinoid medicines, which are present in an unparalleled opportu …
  • Gard P & I (Bermuda) Ltd.
    Gard P & I (Bermuda) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Gard P & I (Bermuda) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Qualyst Transporter Solutions LLC-医療機器分野:企業M&A・提携分析
    Summary Qualyst Transporter Solutions LLC (Qualyst Transporter Solutions), formerly Qualyst Inc is a provider of hepatic drug transporter products and contract research services using B-CLEAR technology. The company offers products such as transporter certified products, transporter interactions, he …
  • Bureau Veritas SA (BVI):石油・ガス:M&Aディール及び事業提携情報
    Summary Bureau Veritas SA (Bureau Veritas) is a provider of testing, inspection and certification services. The company offers asset management, certification, consulting, inspection and audits, testing and analysis, and training. It serves aeronautics, agriculture, automotive, construction and real …
  • SKYCITY Entertainment Group Ltd:企業の戦略・SWOT・財務情報
    SKYCITY Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report Summary SKYCITY Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Banco Santander SA:戦略・SWOT・企業財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Electricity Supply Board:企業の発電所・SWOT分析2018
    Electricity Supply Board - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • American States Water Company (AWR):企業の財務・戦略的SWOT分析
    Summary American States Water Company (AWR) operates as a utility service provider that offers water, wastewater and electric services. The utility provides operation, construction management and maintenance services for water and wastewater systems located on military bases across the US. It offers …
  • TechnipFMC Plc (FTI):企業の財務・戦略的SWOT分析
    TechnipFMC Plc (FTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Ceres Power Holdings Plc (CWR):電力:M&Aディール及び事業提携情報
    Summary Ceres Power Holdings Plc (Ceres Power) is an alternative energy company that develops low cost and next generation fuel cell technologies. The company carries out developing steel cell a fuel cell technology that converts natural gas and hydrogen fuel directly into electrical power and heat …
  • Media General, Inc.:企業のM&A・事業提携・投資動向
    Media General, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Media General, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • OMEICOS Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary OMEICOS Therapeutics GmbH (OMEICOS) is a biopharmaceutical company that develops small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. The company utilizes its proprietary technology of the body’s own omega-3 fatty acid metabolic processes to …
  • Burgan Bank Sak
    Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report Summary Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • British Columbia Ferry Services Inc.:企業の戦略的SWOT分析
    British Columbia Ferry Services Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • KB Home:企業の戦略・SWOT・財務情報
    KB Home - Strategy, SWOT and Corporate Finance Report Summary KB Home - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Enel Generacion Chile SA:企業の発電所・SWOT分析2018
    Enel Generacion Chile SA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆